<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132752">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01829178</url>
  </required_header>
  <id_info>
    <org_study_id>91-03-33-18878</org_study_id>
    <nct_id>NCT01829178</nct_id>
  </id_info>
  <brief_title>Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma</brief_title>
  <official_title>Phase 2-3 Study of Silymarin on Cisplatin Induced Nephrotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <authority>Iran: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cisplatin is a potent chemotherapeutic agent that has been widely used to treat many solid
      tumours. acute renal failure, despite conservative fluid and electrolyte management,
      frequently reported adverse event and limiting cisplatin use. Silymarin, a flavonolignan
      complex isolated from Silybum marianum, has a strong antioxidant, hepatoprotective,
      anticancer and in animal model nephroprotective properties. Neutrophil gelatinase-associated
      lipocalin (NGAL) protein is a promising biomarker to detect acute kidney injury due to
      cisplatin. Milk thistle extract inhibitory effects on epidermal growth factor receptor,
      vascular endothelial growth factor and insulin-like growth factor-I have shown in the
      previous in-vitro studies.The aim of present study,a randomized double-blind placebo-
      controlled clinical trial, to investigate the therapeutic effect of silymarin on cisplatin
      induced nephrotoxicity and it's impact on chemotherapy. Fifty-eight patients with diagnosed
      upper gastrointestinal tract carcinomas randomized to silymarin (420mg) or placebo plus
      chemotherapy [cisplatin 50-60 mg/m2,  5-fluorouracil  mg/m2, docetaxel 60-80 mg/m2 every 21
      days] for 63 day after inclusion. serum creatinin, blood urea nitrogen (BUN), serum and
      urine electrolyte will be measured daily during chemotherapy.

      changes in urine NGAL,  serum vascular endothelial growth factor (VEGF)and caspase activity
      assessed up to 64 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will look for possible protective effects silymarin on kidney injury in patients
      receiving cisplatin.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Urine concentration of NGAL</measure>
    <time_frame>up to 9 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All subject receive silymarin at dose of 420mg or placebo in three dose for 65 consecutive day, urine NGAL concentration will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in VEGF Serum concentration</measure>
    <time_frame>up to 9 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess interaction between silymarin and cancer chemotherapy serum vascular endothelial growth factor will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue activity of caspase 3</measure>
    <time_frame>up to 9 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess interaction between silymarin and cancer chemotherapy Tissue activity of caspase 3will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Upper GI Cancer</condition>
  <condition>Cisplatin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil  750 mg/m2 +docetaxel 60-80 mg/m2]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exprimental: Silymarin and chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Silymarin</intervention_name>
    <description>Silymarin 420 mg in 3 divided dose plus standard chemotherapy</description>
    <arm_group_label>Exprimental: Silymarin and chemotherapy</arm_group_label>
    <other_name>Milk thistle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablets: 420 mg in 3 divided dose</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>Identical inert tablet to mimic silymarin (140 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>All patients will receive  standard chemotherapy: cisplatin 50-60mg/m2 +  fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Exprimental: Silymarin and chemotherapy</arm_group_label>
    <other_name>Cisplatin</other_name>
    <other_name>fluorouracil</other_name>
    <other_name>Docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;18 years

          -  diagnosed

          -  measurable upper gastrointestinal adenocarcinoma

          -  swallow problem

          -  would like to participate in the study

          -  Glomerular filtration rate(GFR)&gt;45ml/min/1.73m2

        Exclusion Criteria:

          -  end stage renal disease

          -  requiring dialysis

          -  post transplantation

          -  receiving contrast media during last 72 hours

          -  chronic use of corticosteroids

          -  chronic use of angiotensin-converting enzyme inhibitor(ACEI )

          -  untreated hypo-and hyperthyroidism

          -  ejection fraction&lt;60%

          -  active urinary tract infection

          -  iver disease ( five fold increase of liver enzyme in asymptomatic or 3 fold increase
             in symptomatic

          -  use of other nephrotoxic agents such as aminoglycoside, amphotericin

          -  karnofsky performance status &lt;70
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tehran University of Medical Science</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>simin dashti, Pharm.D</last_name>
      <email>dashtis@tums.sina.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Simin Dashti, Pharm.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanambar Sadighi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saeed Hashemi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Foroud Shahbazi, Pharm.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Hossein Ghahremani, Pharm.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alireza Addolahi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 8, 2013</lastchanged_date>
  <firstreceived_date>January 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cisplatin</keyword>
  <keyword>nephrotoxicity</keyword>
  <keyword>antioxidant</keyword>
  <keyword>urine neutrophil gelatinase-associated lipocalin (NGAL)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
